Navigation Links
Covagen Names Elias Papatheodorou Chief Business Officer

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.

Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the business development efforts for the company's pipeline and technology and closed the Asian-Australian licensing agreement for Medigene's lead oncology asset to Syncore. Prior to Medigene, Mr. Papatheodorou was chief executive officer of Novosom where he completed a series of collaborative agreements with pharmaceutical companies in Europe, U.S. and Asia, led the company's fundraising activities and ultimately closed the sale of Novosom's Smarticles technology to Marina Biotech. Mr. Papatheodorou was also vice president of business development and marketing for the medical imaging company A.T.I. and held positions of increasing responsibility at The Coca-Cola Company and Philip Morris.

"We are fortunate to have someone with Elias' experience join our executive team, particularly as we continue to validate our bispecific FynomAb™ technology and prepare to bring our lead drug candidate COVA322, a bispecific TNF/IL-17A inhibitor, into the clinic," said Franz Hefti , chairman of the board of Covagen. "The flexibility of the architecture of our FynomAbs is unique in bispecific technology and Elias will play a key role in advancing discussions with potential partners."

Mr. Papatheodorou holds a bachelor's degree from Ithaca College and graduate education from Cornell University.

About CovagenCovagen develops bispecific FynomAbs™ by fusing its human Fynomer™ binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers™ to multiple sites on an antibody allows Covagen to create FynomAbs™ with tailored architecture to maximize efficacy. FynomAbs™ maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. Covagen is actively moving COVA322, its lead bispecific anti-TNF/IL-17A FynomAb™, through development and expects to initiate a Phase I/IIa trial in patients with psoriasis in the first quarter of 2014.

For more information, please visit Contact:

Media Contact:Julian Bertschinger, Ph.D.Matt Middleman, M.D.Chief Executive OfficerRusso PartnersTel: +41 (0) 44 732 4Tel: +1 212 845 

SOURCE Covagen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President and General Counsel
2. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
3. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
4. Halozyme Therapeutics Names Matt Posard to Board of Directors
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Bausch + Lomb Names Robert Bertolini President And Chief Financial Officer
7. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
8. PeriGen, Inc. Names American Journal of OBGYN Editor-In-Chief Thomas J. Garite MD, Chief Clinical Officer
9. Dynamic Healthcare Services Names Senior Level Management Team
10. Hello Health Inc. Names Barry Holleman Executive Vice President, Chief Operating Officer
11. SkilaMederi Names Ray Joske as Chief Commercial Officer
Post Your Comments:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):